In inflammation-associated progressive neuroinflammatory disorders, such as multiple sclerosis (MS), inflammatory infiltrates containing T helper 1 (T H 1) and T H 17 cells cause demyelination and neuronal degeneration. Regulatory T cells (T reg ) control the activation and infiltration of autoreactive T cells into the central nervous system (CNS). In MS and experimental autoimmune encephalomyelitis (EAE) in mice, T reg function is impaired. We show that a recently approved drug, Nle 4 -D-Phe 7 -a-melanocyte-stimulating hormone (NDP-MSH), induced functional T reg , resulting in amelioration of EAE progression in mice. NDP-MSH also prevented immune cell infiltration into the CNS by restoring the integrity of the blood-brain barrier. NDP-MSH exerted long-lasting neuroprotective effects in mice with EAE and prevented excitotoxic death and reestablished action potential firing in mouse and human neurons in vitro. Neuroprotection by NDP-MSH was mediated via signaling through the melanocortin-1 and orphan nuclear 4 receptors in mouse and human neurons. NDP-MSH may be of benefit in treating neuroinflammatory diseases such as relapsingremitting MS and related disorders.
INTRODUCTION
Neuroinflammatory disorders, such as multiple sclerosis (MS) or Devic's disease, are characterized by an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS) leading to severe disability and have an estimated prevalence of more than 2.5 million cases worldwide (1) . They are mediated by peripherally generated autoreactive T cells infiltrating into the CNS, where they are restimulated by antigen-presenting cells, resulting in local expansion of pathogenic T helper 1 (T H 1) and T H 17 cells, tissue damage to oligodendrocytes, and, subsequently, a secondary infiltration of bystander immune cells, controlling the disease's perpetuation (2, 3) . Regulatory T cells (T regs ) are involved in limiting the activation, proliferation, and infiltration of pathogenic effector cells into the CNS (1, 4) . However, in MS and the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, an altered distribution, modified phenotype, and, particularly, impaired suppressive activity of T reg have been associated with disease progression (5-7). Accordingly, immunomodulatory drugs known to induce anti-inflammatory pathways and functional T reg , such as glatiramer acetate, fingolimod, or interferon-b, at least partially ameliorate disease in MS and EAE by up-regulating T reg numbers or increasing their suppressor function (8) (9) (10) . Although these drugs attenuate proinflammatory T cell responses, there is doubt that they directly protect neurons from inflammatory cell death (11, 12) . Consequently, in a model of opticospinal encephalomyelitis involving myelin oligodendrocyte glycoprotein (MOG)-specific T and B cells, glatiramer acetate treatment only resulted in a nonsignificant trend toward lower disease activity (13) .
The neuropeptide a-melanocyte-stimulating hormone (a-MSH) is a known mediator of skin pigmentation, but it also acts as a potent immunomodulator capable of expanding thymus-derived and peripherally induced T reg , which inhibits the proliferation of mouse and human T H 1 and T H 17 cells in psoriasis (14) . The biologic effects of a-MSH are mediated by binding to one of five heterotrimeric guanine nucleotidebinding protein-coupled melanocortin receptors (termed Mc1r to Mc5r) (15, 16) . All five melanocortin receptors are highly expressed on neuronal cells in the CNS, and particularly Mc1r, which has been shown to mediate the immunomodulatory effects of a-MSH, can additionally be found on immune cells (14, 16, 17) . Mc1r is functionally coupled to adenylyl cyclase. Hence, the majority of Mc1r-mediated effects of a-MSH are based on the activation of cyclic adenosine monophosphate (cAMP)-dependent signaling pathways. These include the activation of protein kinase A, the phosphorylation of cAMP response element-binding protein (CREB), the reduction of nuclear factor of activated T cells (NFAT) activity, or the suppression of nuclear factor kB (NF-kB) translocation through the protection of inhibitor of nuclear factor kB a (IkBa) from phosphorylation (18, 19) . Under physiologic conditions, cells of the CNS are a source of a-MSH, and in vitro studies suggest a possible neuroprotective role because melanocortin inhibited NF-kB activation in tumor necrosis factor a-activated rat Schwann cells or lipopolysaccharide-activated human glioma cells (20, 21) . However, a-MSH is chemically unstable, highly sensitive to proteolytic degradation, and undetectable in the plasma 30 to 90 min after intravenous injection (22) . Accordingly, the neuropeptide has been modified at the amino acids in positions 4 and 7, resulting in the protease-stable Nle
RESULTS

MSH ameliorates progression of EAE by binding to Mc1r
To characterize the impact of melanocortins on the development of inflammatory neurodegeneration, we immunized C57BL/6 (wild-type) mice with MOG peptide and systemically treated them with a-MSH in 48-hour intervals. a-MSH completely protected mice from developing clinical signs of EAE, and this effect was associated with reduced inflammatory foci and decreased CNS demyelination [ Fig. 1 , A (P < 0.0001) and B, and fig. S1 (P = 0.0051)]. T H 1 and T H 17 cells were reduced in the CNS and draining cervical lymph nodes from a-MSH-treated mice compared with phosphate-buffered saline (PBS)-injected controls (P = 0.022, T H 1 and P = 0.016, T H 17) , whereas we detected similar levels of both cell subsets in the spleen (Fig. 1C and fig. S2 , A and B). Upon coculture with MOG-loaded dendritic cells (DCs), total CD4 + T cells isolated from the CNS of a-MSH-treated MOG-immunized mice showed a reduced antigen-specific proliferation versus CD4 + T cells from PBS-treated controls ( fig. S2C ; P = 0.029), pointing to the a-MSHmediated induction of T reg in inflammatory neurodegeneration, which was confirmed by flow cytometry, histology, and gene expression studies (25) , and thus, a-MSH exerted its immunomodulatory capacities in an indirect manner by inducing tolerogenic DCs (Fig. 1F  and fig. S3E ). The beneficial effect of a-MSH may be mediated by signaling through Mc1r because treatment of mice deficient in Mc1r or injection of wild-type mice with the C-terminal tripeptide of a-MSH (KPV), which is known to have similar anti-inflammatory capacities but lacks the Mc1r binding motif (15) , did not abrogate disease development (Fig. 1, G and H, and fig. S4, A to D) .
Under physiologic conditions, a-MSH is synthesized directly in the CNS (axons expressing a-MSH are detectable in various cortical areas, but especially in the limbic cortical regions) and is rapidly degraded (22) . Hence, melanocortins resistant to enzymatic cleavage, such as NDP-MSH, have been generated. Given that NDP-MSH (Scenesse) has recently been approved for treating erythropoietic porphyria, we investigated whether NDP-MSH might be able to ameliorate progressive EAE. Therefore, mice were immunized with MOG peptide, and after onset of paralysis (clinical score of ≥2), NDP-MSH was injected every 48 hours. After the third injection, NDP-MSH recipients went into remission, whereas PBS-treated mice showed continued disease progression ( Fig. 2A ; P < 0.0001, clinical score and P < 0.0001, body weight). This was associated with markedly decreased numbers of pathogenic T H 1 and T H 17 effector T cells (Fig. 2 , B and C) as well as increased numbers of T reg in the CNS and reduced inflammatory foci and demyelination (Fig. 2, D and E) of NDP-MSH-treated compared with PBS-treated mice. Similar to a-MSH, NDP-MSH exerted its biological effects by inducing tolerogenic DCs ( fig. S5 , A to C). Notably, the anti-inflammatory capacity of NDP-MSH was increased compared to a-MSH and, similar to a-MSH, was dependent on signaling via a functional Mc1r (Fig. 2, A to E, and fig. S6 , A to D), which was most likely due to the improved stability of the peptide and affinity of NDP-MSH for Mc1r. In NDP-MSH-treated mice, reduction of disease severity was paralleled by decreased numbers of inflammatory lesions containing mononuclear cell infiltrates, less demyelinated areas, and a significantly down-regulated expression of Rab interactive lysosomal protein-like 2 (RILPL2) or amyloid precursor protein (APP), markers known to correlate with CNS inflammation and neurodegeneration in the CNS (Fig. 2, D and E) . In vivo magnetic resonance imaging (MRI) of MOG-immunized mice 6 days after the first injection of NDP-MSH or PBS revealed striking alterations in periventricular signal enhancement due to accumulation of the contrast agent (gadoliniumdiethylenetriaminepentaacetic acid) between NDP-MSH-treated and PBS-treated mice (Fig. 2F ). These observations point to an improved integrity of the endothelial/parenchymal basement membrane in NDP-MSH-treated mice and suggested BBB leakage in control animals (Fig.  2F) . We have previously shown that BBB integrity and T cell extravasation in EAE are controlled by endothelial basement membrane laminins, whereby laminin-a5 (Lama5), which is not homogeneously expressed during CNS inflammation, hampers leukocyte infiltration into the brain (26) . Therefore, immunofluorescence staining of EAE CNS tissue using an antibody to Lama5 was performed. Surprisingly, a uniform expression of Lama5 was detectable in the basement membrane of NDP-MSH-treated mice, whereas PBS-treated controls showed the expected patchy staining ( Fig. 2G ; P = 0.0003). Moreover, extravasation of pathogenic effector T cells, as evidenced by staining for CD4 and interleukin-17 (IL-17), was only detectable in PBS-treated mice at sites lacking Lama5 (Fig. 2G) . To further confirm an improved BBB integrity upon NDP-MSH treatment, we intravenously injected mice with fluorescein isothiocyanate (FITC)-labeled dextran particles, and the extravasation of the beads into the CNS was quantified. The number of dextran particles was reduced in the spinal cord of NDP-MSH-treated mice compared with controls ( Fig. 2H ; P = 0.005, spinal cord; P = 0.57, cerebellum; P = 0.53, cortex; P = 0.49, hippocampus; P = 0.76, thalamus), suggesting that NDP-MSH restored BBB function during CNS inflammation.
Because pertussis toxin is known to permeabilize endothelial barriers (27) and, moreover, the administration of complete Freund's adjuvant might up-regulate Toll-like receptor signaling, thus potentially resulting in the activation of immune cells, we intended to overcome these limitations of MOG-induced EAE by investigating the effects of NDP-MSH in a second, independent, spontaneous model of inflammatory/demyelinating diseases of the CNS. Hence, TCR MOG × IgH MOG mice (a model of Devic's disease) (28) were treated with NDP-MSH starting at a clinical score of ≥2. Mice with Devic's disease developed ascending paralysis 5 to 6 weeks after birth and reached a disease maximum (severest symptoms of the disease that are allowed by animal welfare regulations) at the age of 40 to 50 days for PBS-treated controls (Fig. 3A) . Notably, mice injected with NDP-MSH had a lower cumulative score and were almost completely in remission after 28 days of treatment, whereas PBS-treated controls had to be killed at the age of 7 weeks because of animal welfare regulations ( Fig. 3A ; P = 0.029, clinical score and P = 0.016, body weight). In addition to clinical signs, NDP-MSH markedly reduced the infiltration of total CD4 + T cells into the spinal cord as well as pathogenic T H 1 and T H 17 cells in the periphery (Fig. 3 , B and C), which resulted in less inflammatory foci, demyelinated areas, and down-regulated expression of neuronal/axonal damage markers compared with controls (Fig. 3D) . Also in mice spontaneously developing a Devic-like disease, NDP-MSH induced a uniform expression of Lama5 in the basement membrane, most likely accounting for the reduced T cell infiltration into the CNS of treated mice versus controls (Fig. 3E) . Next, we characterized the duration of the NDP-MSH-mediated protective effect in mice with Devic's disease. Therefore, treatment was terminated at day 64 when mice were in remission, and animals were monitored for disease relapse for up to 5 months. As depicted in Fig. 3F , the beneficial effect of NDP-MSH persisted for at least 60 days without any treatment, and we did not observe alterations in the clinical score until day 124. Thereafter, mice started to develop ascending paralysis (Fig. 3F) , indicating that 14 initial intravenous injections of NDP-MSH from days 36 to 64 were sufficient to keep Devic mice in remission for more than 8 weeks before recurrence of disease activity. Notably, NDP-MSH-treated Devic mice in remission (day 124) showed fewer demyelinated areas in the CNS, a uniform expression of Lama5 in the basement membrane, and a reduced infiltration of T H 1 and T H 17 cells into the spinal cord compared with NDP-MSH-treated Devic mice after recurrence of disease activity (day 194; Fig. 3 , G and H).
NDP-MSH-mediated expansion of T reg or induction of tolerogenic DCs does not account for long-lasting neuroprotection
To analyze whether the generation of tolerogenic DCs and induction of T reg explained the beneficial effect of NDP-MSH in vivo, we depleted T reg in DEREG mice (29) and DCs in CD11c.DOG mice (30) and subsequently induced EAE by injecting the mice with MOG (the efficiency of cell depletion is depicted in fig. S7 , A to D). However, mice lacking T reg or DCs were still protected from disease progression upon NDP-MSH injection (Fig. 4, A to F) , clearly indicating an additional mechanism of NDP-MSH action besides inducing immunosuppressive cell subsets. This hypothesis was further strengthened by the observations in Devic mice, where it was difficult to explain the long-lasting effect of NDP-MSH (even in the absence of the drug; Fig. 3F ) exclusively by the expansion of T reg or tolerogenic DCs. Thus, our data pointed to a direct neuroprotective effect of NDP-MSH in vivo.
NDP-MSH induces neuroprotection and restores action potential generation by up-regulating the orphan nuclear receptor Nr4a1 To identify mechanisms associated with NDP-MSH-mediated neuroprotection, we performed gene expression studies in CNS tissue from MOG-immunized, NDP-MSH-treated, or PBS-treated mice. Surprisingly, upon NDP-MSH treatment, we detected the regulation of gene clusters linked to immune responses in C57BL/6J
e/e mice, whereas in wild-type mice, the regulated gene clusters were linked to pathways associated with neuropeptide/neurotransmitter receptor activity, nervous system development, or neuron fate ( fig. S8 , A to C). In the most prominent gene cluster up-regulated upon NDP-MSH treatment in the CNS of MOG-immunized wild-type mice, we identified the orphan nuclear treated with glutamate, known to cause neuronal cell death (34), in the absence or presence of NDP-MSH. Notably, in glutamate-treated wildtype mouse neurons, NDP-MSH up-regulated both receptors Mc1r and Nr4a1 and blocked the expression of the proapoptotic caspases 3 and 8 ( Fig. 5, A and B) . In contrast, we did not observe the induction of either receptor or down-regulation of proapoptotic caspases in glutamatestimulated neurons from C57BL/6J e/e mutant mouse (Fig. 5, A and B ), indicating that Mc1r signaling is essential for the prevention of neuronal damage via up-regulation of Nr4a1. Next, we analyzed the signaling pathway linking Mc1r and Nr4a1 in mouse neurons. Because Mc1r is known to exert its downstream effects by phosphorylation of CREB or p38 mitogen-activated protein kinase (MAPK) and Nr4a1 can be activated by either pathway (16, 35, 36) , we quantified phospho-CREB and phospho-p38 MAPK in neurons from wild-type and C57BL/6J
e/e mice. Mc1r ligation by NDP-MSH resulted in an increase of phospho-CREB, whereas the neuropeptide did not modulate phospho-p38 MAPK expression (Fig. 5C ), indicating that the direct protective effect of NDP-MSH was mediated by binding to Mc1r, phosphorylation of CREB, and subsequent activation of Nr4a1.
Next, we questioned whether NDP-MSH was able to preserve functional neuronal integrity under glutamate-mediated excitotoxic conditions. Using whole-cell patch-clamp recordings in the current-clamp mode, we detected a resting membrane potential of −53 ± 1.3 mV or −50 ± 1.1 mV (n = 25; P = 0.171) for untreated or NDP-MSH-treated cultured mouse hippocampal neurons, respectively (Fig. 5, D and E). This was accompanied by normal generation of action potentials in untreated mouse neurons triggered by a depolarizing current step (Fig. 5E ), whereas NDP-MSH treatment resulted in an increased number of fired spikes. Application of 10 mM glutamate induced a massive depolarization in untreated hippocampal neurons toward −31.11 ± 2.12 mV (n = 22; P = 0.001), resulting in a depolarization block without any action potential generation. Pretreatment with NDP-MSH prevented glutamate-induced depolarization (40.74 ± 1.568 mV; n = 30; P = 0.0005), allowing all recorded neurons to respond to the current stimulus with action potential generation, although action potential numbers, width, and height differed from control conditions (Fig. 5, D 
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again suggesting that binding of NDP-MSH to Mc1r and signaling via Nr4a1 were essential for the neuroprotective effect of NDP-MSH.
Nr4a1 deficiency abolished the beneficial effect of NDP-MSH
To investigate whether the neuroprotective effect of NDP-MSH was indeed mediated by Nr4a1 signaling in vivo, Nr4a1-deficient mice (Nr4a1 −/− ) (37) were immunized and treated with NDP-MSH. Notably, mean clinical scores and neuronal damage, as evidenced by demyelination and RILPL2 or APP expression, were similar in NDP-MSH-treated Nr4a1 −/− mice and PBS-injected control mice, although NDP-MSHtreated animals had increased numbers of T reg and showed downregulation of pathogenic T H 1 and T H 17 cells in the CNS (Fig. 6, A to  D) , thus indicating that Nr4a1 deficiency abolished the beneficial effect of NDP-MSH. Additionally, in the absence of Nr4a1, NDP-MSH was not able to improve BBB integrity, as indicated by a patchy Lama5 expression and the infiltration of pathogenic T H 17 cells into the CNS at sites with low or absent Lama5 (Fig. 6E) in NDP-MSH-treated Nr4a1 −/− mice. To clearly distinguish the neuroprotective effect of NDP-MSH from its anti-inflammatory capacities, we generated bone marrow chimeric mice by transferring wild-type or Nr4a1 −/− bone marrow cells into lethally irradiated wild-type or Nr4a1 −/− recipients. After having confirmed bone marrow reconstitution ( fig. S10A ), EAE was induced in the chimeric mice. Notably, NDP-MSH entirely ameliorated ongoing EAE in wild-type recipients of Nr4a1 −/− bone marrow, whereas in Nr4a1
recipients of wild-type bone marrow, NDP-MSH had a mild, but nevertheless significant, effect, indicating that both the anti-inflammatory and neuroprotective properties of NDP-MSH were crucial ( Fig. 6F ; P < 0.0001, Nr4a1 −/− + Cd45.1 bone marrow and P = 0.0038 Cd45.1 + Nr4a1 −/− bone marrow). However, the neuroprotective effect of NDP-MSH seemed to be of major importance compared to the anti-inflammatory effect during amelioration of CNS inflammation and degeneration, because we observed complete remission in chimeric mice with wild-type neurons, but only partial remission in chimeric mice with neurons of Nr4a1 −/− origin ( Fig. 6F and fig. S10B ). In support of this, MOG-immunized chimeric mice with wild-type neurons and immune cells of Nr4a1 −/− origin showed almost no demyelinated areas in the CNS upon NDP-MSH treatment and exhibited a continuous Lama5 expression in the basement membrane, preventing the extravasation of pathogenic effector cells into the CNS. In contrast, we observed demyelination and a moderate immune cell infiltrate in the CNS of Nr4a1 −/− recipients of wild-type bone marrow (Fig. 6, G and H, and fig. S10C ). To identify nonhematopoietic cells in the brain, besides neurons, expressing Nr4a1, immunofluorescence staining was performed, demonstrating the presence of the nuclear orphan receptor Nr4a1 in astrocytes, oligodendrocytes, and microglia ( fig. S11 ).
NDP-MSH protected human neurons from glutamate-induced apoptosis Next, we characterized the neuroprotective effect of NDP-MSH in human neurons. Human neurons were differentiated from the ReNcell VM progenitor cell line (38) and treated with glutamate in the absence or presence of NDP-MSH. Similar to murine cells, human neurons expressed MC1R and up-regulated NR4A1 mRNA and protein in response to NDP-MSH (Fig. 7, A and B) . Moreover, in NDP-MSHtreated human neurons, we observed a significant down-regulation of the proapoptotic caspase 3 after glutamate-induced excitotoxicity compared with PBS-treated controls ( + cells, NDP-MSH + Glu versus Glu), suggesting that MC1R/NR4A1 signaling plays a critical role in neuroprotection and the prevention of apoptosis in human neurons. Finally, we assessed whether MC1R/NR4A1 interactions might be involved in the development or progression of MS. Therefore, the expression of MC1R and NR4A1 was quantified in postmortem human brain tissue from individuals with MS. The expression of MC1R was reduced in NEUN + neurons from MS brains compared with controls ( Fig. 7C ; P = 0.0004, total MC1R + cells, MS versus healthy human brain; P = 0.84, total NR4A1 + cells, MS versus healthy human brain; P = 0.0002, MC1R + NR4A1 + cells, MS versus healthy human brain), thus resulting in decreased numbers of neurons expressing both NR4A1 and MC1R. Hence, our data suggest that in MS, because of the reduced expression of MC1R, melanocortins might not be able to exert sufficient neuroprotective effects, thus resulting in increased damage, demyelination, and immune cell infiltration into the CNS.
DISCUSSION
Here, we demonstrated that NDP-MSH efficiently inhibited ongoing inflammation-associated and progressive degenerative disorders of the CNS. This effect was mediated by a combination of the potent antiinflammatory and immunomodulatory capacities of NDP-MSH with the NDP-MSH-induced long-lasting neuroprotection and repair of BBB leakage (Fig. 8, A and B) . At a cellular level, NDP-MSH, by binding to Mc1r, prevented excitotoxic cell death in murine as well as human neurons and partially restored their function. Mechanistically, Mc1r ligation resulted in the downstream phosphorylation of CREB and subsequent CREB-dependent activation of Nr4a1, leading to the induction of neuroprotective genes and presumably also to the up-regulation of Lama5 (Fig. 8B) .
Targeting melanocortin receptors to control peripheral inflammation has frequently been used. Accordingly, the administration of a-MSH to mice or rats with psoriasis, colitis, rheumatoid arthritis, or infections resulted in a marked amelioration of disease mediated by the suppression of pathogenic effector cells, the down-regulation of proinflammatory cytokines, and the induction of anti-inflammatory cytokines (14, (39) (40) (41) . Because some immunomodulatory properties of the melanocortin system, including the induction of functional T reg (14) , might be relevant to CNS inflammation, we assessed the therapeutic potential of NDP-MSH, a melanocortin peptide recently approved for the treatment of certain skin diseases, during established inflammatory and degenerative CNS disorders. Surprisingly, NDP-MSH induced complete remission in MOG-induced EAE as well as in Devic's disease in mice even after just a few intravenous injections. This observation was in stark contrast to previous studies showing a 24-hour delay in disease onset and a 50% decreased disease severity after daily oral administration of a-MSH starting 7 days before MOG immunization or a reduction in clinical score from 2.1 to 1.3 after a-MSH treatment of proteolipid protein-immunized mice (42, 43) . However, the mild effects of a-MSH (42, 43) might be attributed to its chemical instability. To overcome this problem, mice were treated with proteolipid protein-induced EAE with Ac-SVa-MSH, an a-MSH analog, in which the amino acids Tyr, Ser, and Phe in positions 2, 3, and 7 were replaced by Ser, Ile, and D-Phe to increase the stability and affinity to Mc1r as well as Mc5r (18) . However, only the preemptive administration starting at the day of immunization resulted in a reduction of disease severity, whereas Ac-SVa-MSH injected after onset of paralysis had no effect (18) . Because we have shown that the protective effect in inflammation-associated CNS diseases is mediated by ligation of Mc1r (Figs. 1G and 8B) , the different efficacy of Ac-SVa-MSH and NDP-MSH might be explained by the specificity of NDP-MSH for Mc1r, whereas Ac-SVa-MSH binds to Mc1r and Mc5r with similar affinity (18, 23, 24) . However, this is unlikely to explain the long-lasting beneficial effect of NDP-MSH, particularly in Devic's disease (>8 weeks of remission without any treatment), just by the induction of T reg . In line with this, by depleting T reg , performing gene expression studies, conducting functional assays in isolated neurons, and generating bone marrow chimeric mice, we identified the direct neuroprotective potential of NDP-MSH in inflammation-associated and progressive degenerative CNS diseases. The ability of melanocortins to reduce neuronal damage after traumatic brain injury or counteract cognitive decline in mice with Alzheimer's disease has already been discussed (44, 45) ; however, the underlying molecular mechanisms have not yet been elucidated. Here, we clearly demonstrated that NDP-MSH induces neuroprotection by binding to Mc1r, resulting in subsequent activation of Nr4a1 via phosphorylation of CREB (Figs. 5C and 8B) . Nr4a1 belongs to a family of orphan nuclear receptors for which, thus far, no physiologic ligand has been identified (46) . In mice or humans, this family consists of three receptors: Nr4a1 (also known as Nur77), Nr4a2 (Nurr1), and Nr4a3 (Nor-1). All three Nr4a receptors are involved in basic cellular processes like proliferation, apoptosis, differentiation, and stress responses (46) . Nr4a2 seems to be crucial for the development of dopaminergic neurons as concluded from Nr4a2 −/− mice presenting with severe defects in brain architecture (47) . Additionally, in EAE mice, the activation of Nr4a2 with isoxazolo-pyridinone reduced disease severity and was suggested to attenuate neurodegeneration (48) . Nr4a1 has been implicated in neuroprotection because this receptor was up-regulated upon excitotoxic and oxidative stress in mouse hippocampal neurons and mediated the induction of neuroprotective genes, such as Abl2, Prkaa2, or Sod1 (31). Notably, in melanocytes, Nr4a1 expression can be regulated in response to Mc1r signaling (33) . In line with these observations, upon NDP-MSH treatment, we were unable to detect Nr4a1 in hippocampal neurons from C57BL/6J
e/e mice lacking a functional Mc1r. Whereas we have shown the restoration of action potential firing in neurons, Yin et al. demonstrated an augmented DNA repair in ultravioletirradiated keratinocytes after ligation of Mc1r and induction of Nr4a1 (32), thus suggesting the general protective potential of this pathway.
Experiments in bone marrow chimeric mice clearly revealed that a combination of the anti-inflammatory and neuroprotective properties of NDP-MSH was essential to induce the observed long-lasting beneficial effect in inflammation-associated and degenerative diseases of the CNS. In this context, a critical hallmark of NDP-MSH might be the restoration of BBB integrity, which we detected in mice with active EAE and Devic's disease. Besides immune cells and neurons, Mc1r is expressed on endothelial cells, including brain endothelial cells, and ligation of Mc1r protected against endothelial dysfunction (47, 49) . This protective effect was abrogated in C57BL/6J e/e mice, which showed an increased arterial stiffness and susceptibility to inflammation-driven vascular dysfunction (50) . Besides Mc1r, Nr4a1 is also rapidly induced in endothelial cells upon treatment with proinflammatory stimuli, resulting in improved cell survival (51) . In contrast, knockdown of Nr4a1 induced endothelial cell apoptosis (51) . Furthermore, it has been shown that Nr4a1 overexpression led to decreased monocyte adhesion to endothelial cells (52) . Additionally, a-MSH by binding to melanocortin receptors inhibited the transmigration of neutrophils across an endothelium-epithelium bilayer under inflammatory conditions (53) . Hence, it is conceivable that Mc1r and Nr4a1, besides inducing direct neuroprotection, also cooperate in improving the function of the BBB during CNS inflammation by protecting endothelial cells from damage and preventing leukocyte transmigration. A characteristic hallmark of impaired BBB integrity during CNS inflammation is the nonhomogeneous expression of Lama5. We have previously demonstrated that basement membrane laminins control leukocyte extravasation into the CNS, whereas Lama5 hampers this migration, thus enabling leukocyte infiltration into the brain only in areas with little or no Lama5 expression (26) . NDP-MSH induced a continuous Lama5 expression in the basement membrane of the BBB, thereby improving BBB integrity and preventing leukocyte extravasation. These observations might suggest that in endothelial basement membranes of the CNS, the protective synergistic effect of Mc1r and Nr4a1 signaling could, besides preventing damage of endothelial cells, also include the induction of Lama5, thus conferring an impermeability to the BBB. Alternatively, the anti-inflammatory effects of NDP-MSH could have contributed to the improvement of BBB integrity.
Besides anti-inflammatory and immunomodulatory capacities, we detected a strong and direct neuroprotective effect of NDP-MSH in mouse neurons as well as in human neurons, which, in combination with the restoration of BBB integrity and reduced leukocyte infiltration into the brain, led to long-lasting CNS protection. Because NDP-MSH has recently been approved by the European Medicines Agency for the treatment of erythropoietic porphyria, our data suggest that this drug could be used for the treatment of inflammation-associated degenerative CNS diseases, such as relapsing-remitting MS. Under physiologic conditions, melanocortins, such as a-MSH, are expressed in the brain (19) (20) (21) . However, as we have shown, Mc1r expression is down-regulated in MS compared with the healthy human brain (Fig. 7C) . Thus, it is conceivable that the naturally occurring a-MSH, which is characterized by a lower affinity for Mc1r compared with the synthetic NDP-MSH, might not be potent enough to induce neuroprotection and BBB repair in individuals with MS. This could potentially be overcome by treatment with NDP-MSH; however, more studies are needed to fully delineate the benefits of NDP-MSH in neuroinflammatory diseases.
MATERIALS AND METHODS
Study design
The aim of this study was to characterize the therapeutic potential of the recently approved drug NDP-MSH (Scenesse) in progressive neuroinflammatory diseases. Therefore, mouse models of active (MOGinduced) and spontaneous EAE (Devic's disease) were used, revealing an anti-inflammatory as well as long-lasting neuroprotective effects of NDP-MSH even after drug treatment was halted. To elucidate the underlying molecular mechanisms, gene expression profiling using Affymetrix Mouse Gene 2.0 ST Gene Expression Microarrays was performed, pointing to a crucial role of Mc1r and Nr4a1 signaling in NDP-MSH-mediated neuroprotection. Electrophysiology studies demonstrating that the NDP-MSH-mediated restoration of action potential firing even under excitotoxic conditions was dependent on the presence of functional melanocortin-1 and nuclear orphan 4 receptors confirmed the gene expression data. To directly translate these observations, human neurons were differentiated from neural progenitor cells and treated with glutamate to induce excitotoxicity in the absence and presence of NDP-MSH. Data showed that in human neurons, NDP-MSH mediated direct neuroprotection via signaling through MC1R and NR4A1. Additionally, MC1R and NR4A1 were quantified in human neuronal cells and postmortem brain tissue from healthy donors as well as MS patients, revealing markedly down-regulated MC1R expression in the MS brain. Thus, the approved drug NDP-MSH, which is characterized by a high affinity for MC1R, might represent a new option for the treatment of inflammatory and degenerative diseases of the CNS.
All animal experiments and studies involving human material were approved by the responsible authorities as indicated in the methods. Experiments were conducted until statistical significance was reached, and a simple randomization to the treatment groups (control versus NDP-MSH) was achieved by flipping a coin. No animals or samples in any of the experiments were excluded from data analyses, which in some figures resulted in slightly increased error bars.
Animal studies C57BL/6 (wild-type; purchased from Janvier Labs), DEREG (29) , C57BL/6J
e/e (characterized by a point mutation in the Mc1r gene leading to a nonfunctional receptor; The Jackson Laboratory), TCR MOG × IgH MOG (28) , CD11c.DOG (30) , and NGFI-B −/− mice (Nr4a1 −/− ) (37) were used at the age of 8 to 12 weeks and housed under specific pathogen-free conditions in microisolator cages. Mice were given chow and water ad libitum and monitored for clinical signs daily. Consistent with animal welfare law, mice received a high-fat and high-protein diet beginning at a clinical score of 3. All animal experiments were performed with the approval of the State Review Board of North RhineWestphalia according to the German law for animal welfare, reference no. 84-02.04.2013-A139.
Induction of EAE in mice EAE was induced by subcutaneous injection of 200 mg of MOG peptide (MEVGWYRSPFSRVVHLYRNGK; Charité, Berlin, Germany) emulsified in complete Freund's adjuvant (Sigma-Aldrich) containing 200 mg of Mycobacterium tuberculosis H37RA (Difco). Pertussis toxin (400 ng; Enzo Life Sciences) in 200 ml of PBS was injected intraperitoneally at the day of immunization and 2 days later. Disease severity was scored daily in a blinded fashion by two independent investigators using a scale from 0 to 10 (experimental autoimmune neuritis score) (54) .
Pharmacological treatment of mice a-MSH, KPV, KdPT, or NDP-MSH (all purchased from Bachem) was injected intravenously at a concentration of 5 mg in 100 ml of PBS every 48 hours when immunized mice reached a clinical score of ≥2. Control mice received an equal amount of PBS (PAA Laboratories).
Depletion of T reg and CD11c
+ DCs Depletion of T reg was achieved by intraperitoneal injection of DT (Sigma-Aldrich) at a concentration of 50 ng/g body weight into DEREG mice. CD11c + DCs were depleted by intraperitoneal injection of DT at a concentration of 8 ng/g body weight into CD11c.DOG mice. DT was injected on a daily basis for six consecutive days starting 2 days before MOG immunization. Ablation of T reg or DCs was verified before MOG injection as well as at days 8, 12, and 16 after immunization by multicolor flow cytometry.
Cell preparation and flow cytometry Single-cell suspensions of lymph nodes, spleen, and peripheral blood were prepared according to standard methods. For the isolation of mononuclear cells from the CNS (brain and spinal cord), mice were perfused with PBS through the left ventricle. Subsequently, tissues were homogenized through 100-mm cell strainers to obtain single-cell suspensions, and Percoll gradient centrifugation was performed. The expression of cell surface and intracellular markers was analyzed by multicolor flow cytometry on a Gallios flow cytometer (Beckman Coulter) using Kaluza software. For flow cytometry, cells were stained in PBS using antibodies against CD4 (clone RM4 , and TNF-a (tumor necrosis factor-a) (clone MP6-XT22; all purchased from BioLegend or Miltenyi Biotec) was performed after cell permeabilization using the Fix/Perm Buffer Set (BioLegend) according to the manufacturer's instructions. Isotype-matched controls were included in each staining, and apoptotic cells were identified using an annexin V apoptosis detection kit.
Proliferation and suppression assays CD4 + T cell subsets and DCs were negatively enriched by magnetic cell separation using the appropriate kits (Miltenyi Biotec). T cells were stained with 1 mM carboxyfluorescein succinimidyl ester (CFSE; Life Technologies) and cocultured with DCs pulsed with MOG peptide (10 mg/ml) (DC/T cell ratio, 1:20) for 3 to 5 days at 37°C and 5% CO 2 . Subsequently, CFSE dilution, as a measure of cell proliferation, was quantified by flow cytometry. Dead cells were excluded using TO-PRO-3 iodide staining (Life Technologies).
Suppression assays were performed by labeling 1. Mouse hippocampal neuronal cultures and glutamate excitotoxicity assays Neuronal cell cultures were obtained from wild-type, Nr4a1
e/e embryos (E18) following previously described protocols (55) . Neuronal cultures were incubated at 37°C and 5% CO 2 for 5 to 7 days and stimulated with 1 nM NDP-MSH or an equal amount of PBS two times per day for the last 3 days of the culture. Analysis of excitotoxic neuronal cell damage was performed by treating neuronal cells for 6 hours in standard artificial cerebrospinal fluid (ACSF; 120 mM NaCl, 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 22 mM NaHCO 3 , 2 mM MgSO 4 , 2 mM CaCl 2 , and 20 mM dextrose; pH 7.35 adjusted by bubbling with a mixture of 95% O 2 and 5% CO 2 ) with 50 mM L-glutamate (SigmaAldrich) in the presence or absence of NDP-MSH. Subsequently, neurons were used for gene expression analyses or were fixed in 4% paraformaldehyde for immunofluorescence staining.
Human neuronal cultures and glutamate excitotoxicity assays Human neuronal cells were generated from progenitor cells (ReNcell VM; Merck Millipore) as described (56) . After differentiation, neurons were pretreated with 1 nM NDP-MSH for 3 days. The analysis of excitotoxic neuronal cell damage was performed as described above.
Histology and immunofluorescence staining Mouse tissues (brain and spinal cord) were cryopreserved in Neg-50 (Thermo Fisher Scientific) and cut into 3-mm sections, and immunofluorescence staining was performed using standard methods and the appropriate dilutions of primary antibodies against CD31 (clone ER-MP12, Thermo Fisher Scientific), glial fibrillary acidic protein (clone G-A-5, Sigma-Aldrich), Iba1 (rabbit polyclonal, Abcam), CD11c (clone N418, BioLegend), CNPase (clone 11-5B, Sigma-Aldrich), CD4 (clone RM4-5), RILPL2 (Proteintech), APP (rabbit polyclonal, Cell Signaling Technology), IL-17A (clone eBio17B7), NeuN (clone A60, Merck Millipore), Lama5 (provided by L. Sorokin), Foxp3 (clone FJK-16s), Nr4a1 (Novus Biologicals), Mc1r (Biozol), and cleaved caspase 3 (clone 9664, Cell Signaling Technology). Subsequently, slides were incubated with Alexa Fluor (AF) 647-, AF594-, AF488-, or AF421-coupled secondary antibodies (Life Technologies). Isotype controls were included in each staining, and in some experiments, nuclei were counterstained with DAPI (Sigma-Aldrich).
For H&E as well as LFB (Sigma-Aldrich) staining, tissues were embedded in paraffin and cut into 3-mm sections. After deparaffinization using standard protocols, H&E staining was performed using an autostainer (Tissue-Tek Prisma, Sakura Finetek). For LFB staining, slides were incubated with LFB solution (Sigma-Aldrich) overnight, rinsed with distilled water, and differentiated with 0.05 % lithium carbonate. Subsequently, slides were analyzed on an Olympus BX63 microscope using cellSens software (Olympus).
Human autopsy and biopsy materials from patients with MS were obtained from the Netherlands Brain Bank (NBB), Amsterdam. The NBB provides its ethical authorization for "donation and collection of brain material for scientific research" (Ref. 2009/148; n = 3 subjects). Written informed consent was obtained from all patients, and experiments were carried out according to the Declaration of Helsinki. The lesions fulfilled the morphologic criteria of an inflammatory demyelinating process consistent with MS when stained with H&E, LFB, and periodic acid Schiff, myelin stain, and Bielschowsky's silver impregnation for axons. We classified lesions according to their demyelination status and included early and late active lesions. Staining was performed on 10-mm coronal sections.
RNA isolation and quantitative PCR RNA was extracted from snap-frozen tissues or purified cells using innuPREP-RNA Mini Kit (Analytik Jena) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from 1 mg of total RNA using random hexanucleotide primers and RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Quantitative PCR (qPCR) was performed in a qTower 2.2 PCR system (Analytik Jena) using the KAPA SYBR FAST Universal qPCR Master Mix (VWR International).
All reported mRNA levels were normalized to b-actin or glyceraldehyde phosphate dehydrogenase, and primer sequences are depicted in table S1. Relative mRNA expression was calculated according to the 2 −DDC t method (57).
Bio-Plex assays
Neuronal cells were isolated and stimulated as described. Subsequently, cell lysates were prepared using the Cell Lysis buffer (Bio-Rad) according to the manufacturer's instructions. Total CREB, p38 MAPK, phospho-CREB (Ser   133   ) , and phospho-p38 MAPK (Thr 180 /Tyr 182 ) levels were assessed by using Bio-Plex Pro Magnetic Cell Signaling Assays and a Bio-Plex Magpix multiplex reader (Bio-Rad) according to the manufacturer's protocols. Phosphoproteins were quantified as percentage relative to the total amount of proteins. Cell lysate controls (BioRad) were included in each assay.
Electrophysiology
Neuronal cells were isolated and stimulated as described. Electrophysiology measurements were conducted in the whole-cell currentclamp configuration of the patch-clamp technique. Recording pipettes were purchased from borosilicate glass (GT150TF-10, Clark Electromedical Instruments; typical resistance was 4 to 7 megohms) and filled with an intracellular solution containing 95 mM K-gluconate, 20 mM K 3 -citrate, 10 mM NaCl, 10 mM Hepes, 1 mM MgCl 2 , 0.5 mM CaCl 2 , 3 mM BAPTA [1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid], 3 mM Mg-adenosine triphosphate, and 0.5 mM Na 3 -guanosine triphosphate. The internal solution was set to a pH of 7.25 with KOH and an osmolarity of 295 mOsm/kg. ACSF was used as extracellular solution containing 120 mM NaCl, 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 22 mM NaHCO 3 , 2 mM MgSO 4 , 2 mM CaCl 2 , and 20 mM glucose [pH 7.35 (adjusted by bubbling with a mixture of 95% O 2 and 5% CO 2 )], and osmolarity was set to 305 mOsm/kg. Membrane potentials were recorded using an EPC 10 amplifier, and digital analysis was done using Fitmaster (HEKA Elektronik) and TRACE software.
Magnetic resonance imaging MRI was performed with a 9.4-T small-animal MRI scanner (BioSpec 94/20; gradient strength, 700 mT/m) equipped with a helium-cooled CryoProbe (Bruker BioSpin MRI GmbH). Two anatomical T1-weighted three-dimensional scans were acquired, one before and one 2 min after intravenous administration of Magnevist (100 mmol/kg) into the tail vein, using a gradient echo sequence with a repetition time/echo time of 25/3 ms and a flip angle of 15°. Geometry parameters were a field of view of 15 × 15 mm and an acquisition matrix of 160 × 160 × 96, resulting in an in-plane resolution of 94 mm. Scan time per animal was 12 min 48 s. Scanning was performed under inhalation anesthesia using 1.5% isoflurane (1 liter/min in O 2 /compressed air, 20/80).
Injection of FITC-labeled dextran particles
Amounts of 3-kDa dextran (25 mg/ml) (Life Technologies) were diluted in PBS and injected intravenously into MOG-immunized mice (2.5 mg per mouse) at disease maximum 1 hour before killing. After perfusion, spinal cord, brain, and kidney tissues were isolated and homogenized. Subsequently, supernatants were used for fluorescence quantification on a Tecan Infinite M200 PRO machine (Tecan) at 494 nm/521 nm. Fluorescence intensities in spinal cord and brain were normalized to kidney tissue.
Generation of bone marrow chimeric mice
Eight-week-old recipient mice were sublethally irradiated following standard procedures (58) using a Faxitron irradiator (Faxitron Innovative Röntgentechnik). Subsequently, mice were reconstituted with 7.5 × 10 6 bone marrow cells isolated from femurs and tibias of adult Nr4a1 −/− or wild-type donors on a Cd45.1 or Cd45.2 background. Six to 12 weeks after bone marrow reconstitution, peripheral blood chimerism was assessed by flow cytometry.
Gene expression profiling
Gene expression profiling was performed on total RNA extracted from 5 to 10 mg of brain and spinal cord tissues from wild-type and C57BL/ 6J e/e mice treated with PBS or NDP-MSH at disease maximum. Afterward, total RNA preparations were analyzed for integrity using Agilent 2100 Bioanalyzer (Agilent Technologies). All samples showed high quality (mean RNA Integrity Number 9.3). RNA was further analyzed by photometric NanoDrop measurement and quantified by fluorometric Qubit RNA assays (Life Technologies). Synthesis of biotin-labeled cDNA was performed according to the manufacturer's protocols (WT Plus Reagent Kit; Affymetrix Inc.). Briefly, 100 ng of total RNA was converted to cDNA. After amplification by in vitro transcription and second cycle synthesis, cDNA was fragmented and biotin-labeled by terminal transferase. Finally, end-labeled cDNA was hybridized to Affymetrix Mouse Gene 2.0 ST Gene Expression Microarrays for 16 hours at 45°C, stained by streptavidin/phycoerythrin conjugate, and scanned as described in the manufacturer's instructions. Data analyses on Affymetrix CEL files were conducted using GeneSpring GX software (version 12.5; Agilent Technologies). Probes within each probe set were summarized by GeneSpring's ExonRMA16 algorithm after quantile normalization of probe level signal intensities across all samples to reduce interarray variability (59) . Input data preprocessing was concluded by baseline transformation to the median of all samples. After grouping of biological replicates (duplicates) according to their respective experimental condition, a given probe set had to be expressed above background (that is, a fluorescence signal of a probe set was detected within the 20th and 100th percentiles of the raw signal distribution of a given array) in both replicates in at least one of two, or both, conditions to be further analyzed in pairwise comparisons. Differential gene expression was statistically determined by moderated t tests. The significance threshold was set to P = 0.05. Differentially expressed genes passing a fold change cutoff of >1.5 and a P value of <0.05 in all replicates of one experimental group were further characterized using KOBAS 2.0 software (http://kobas.cbi.pku.edu.cn), and known as well as predicted interactions of proteins encoded by the differentially expressed genes were calculated using STRING 10 software (http://string-db.org). The microarray data are available in the Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/gds) under accession no. GSE73587.
Statistics
All values are expressed as means ± SEM. Statistically significant differences were assessed by paired sign t test ( 
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